Great news for liver cancer patient in Malaysia . How about lung cancer ? Is Lung foundation Of Malaysia working on it too ?

The article in The Star Fit4life today ( 19th June 2011 ) about The NexPAP programme is such a good news to liver cancer patient
http://thestar.com.my/health/story.asp?file=/2011/6/19/health/8926005&sec=health

Thanks to Bayer HealthCare and Malaysian Liver Foundation (MLF).

Meantime, looking forward to Lung foundation of Malaysia to start working on some programme to assist lung cancer patient in Malaysia .

+++++
Sunday June 19, 2011
The NexPAP programme


NexPAP is a programme designed to assist Malaysian patients who have been diagnosed with liver cancer (hepatocellular carcinoma or HCC), and have been prescribed by their doctors to use sorafenib.

The programme aims to provide drug assistance to help patients in continuing with drug treatment for as long as medically required.

This programme is part of Bayer HealthCare Malaysia’s initiatives to provide drug assistance to Malaysian patients.

Bayer HealthCare is working in partnership with the Malaysian Liver Foundation (MLF) to run NexPAP.

As part of NexPAP, patients will purchase the first two months of sorafenib, after which Bayer HealthCare will donate free sorafenib for up to the next 12 months to patients, as long as medically required as determined by the prescribing physician.

How Does NexPAP Work?

1. The patient has been diagnosed with HCC by a medical professional.

2. The patient fulfils the eligibility criteria for NexPAP, such as:

·Malaysian citizenship or permanent residency

·Satisfactory income level based on certain criteria (subject to MLF approval).

·Ability to purchase the first two months’ treatment of sorafenib.

3. The patient to apply for NexPAP to MLF with prescribing doctor’s recommendation.

4. The application will be assessed by MLF based on entry criteria with supporting documentation.

5. The patient will receive application results from MLF via the prescribing doctor.

6. The patient needs to follow up with his/her prescribing doctor monthly for treatment of the disease, but collection of the monthly donation sorafenib will be from MLF.

According to Janice Chow, senior public relations manager with Bayer HealthCare, “We have a long and ongoing commitment to contribute to medical progress and to improve the quality of human health. Each NexPAP beneficiary has a truly heart-warming story to share and we are pleased to be able to help make a difference in their lives. We will continue to work with the Malaysian Liver Foundation on NexPAP to see more liver cancer patients benefit from treatment.”

Since the launch of the progarmme, more than 50 patients have benefited from it.

Patients can apply to the MLF for the NexPAP patient assistance programme with their prescribing doctor’s recommendation. For more information about liver cancer and NexPAP, please contact the foundation at 03-7842 6101.

+++++++